ScholarLens Back to search
2005•Unpublished venueRequires access

Comparative study of citalopram and maprotiline in treatment of depression

Ding Dong-hon

Open publisher page 1 citations

Abstract

Objective:To explore the efficacy and safety of citalopram in the treatment of patients with depression. Method:60 patients with depression were randomly assigned to citalopram group and maprotiline group for six weeks.Hamilton depressive scale(HAMD)、Hamilton anxiety scale(HAMA) and treatment emergent symptom scale(TESS) were used to assess the clinical efficacy and side effects. Results:The significant improvement rate of citalopram was 83.3% and that of maprotiline was 76.7%.There was no significant difference between the two groups.The score of HAMA was reduced more in citalopram group than in maprotiline group.The adverse reactions of citalopram were lower and lighter than that of maprotiline. Conclusion:Citalopram is an effective antidepressant with fewer side effects and takes effect rapidly.

About this research paper

What this paper is about

Objective:To explore the efficacy and safety of citalopram in the treatment of patients with depression. Method:60 patients with depression were randomly assigned to citalopram group and maprotiline group for six weeks.Hamilton depressive scale(HAMD)、Hamilton anxiety scale(HAMA) and treatment emergent symptom scale(TESS) were used to assess the clinical efficacy and side effects. Results:The significant improvement rate of citalopram was 83.3% and that of maprotiline was 76.7%.There was no significant difference between the two groups.The score of HAMA was reduced more in citalopram group than in maprotiline group.The adverse reactions of citalopram were lower and lighter than that of maprotiline. Conclusion:Citalopram is an effective antidepressant with fewer side effects and takes effect rapidly.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To explore the efficacy and safety of citalopram in the treatment of patients with depression. Method:60 patients with depression were randomly assigned to citalopram group and maprotiline group for six weeks.Hamilton depressive scale(HAMD)、Hamilton anxiety scale(HAMA) and treatment emergent symptom scale(TESS) were used to assess the clinical efficacy and side effects. Results:The significant improvement rate of citalopram was 83.3% and that of maprotiline was 76.7%.There was no significant difference between the two groups.The score of HAMA was reduced more in citalopram group than in maprotiline group.The adverse reactions of citalopram were lower and lighter than that of maprotiline. Conclusion:Citalopram is an effective antidepressant with fewer side effects and takes effect rapidly.

Key concepts: Maprotiline, Citalopram, Hamd, Antidepressant, Depression (economics), Hamilton depression scale, Psychology, Rating scale

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Comparative study of citalopram and maprotiline in treatment of depression — Research Paper | ScholarLens